|Mr. Frederic Ors M.B.A., B.Sc., M.A.||CEO & Director||N/A||N/A||1974|
|Mr. Pierre LabbÃ© C.A., C.P.A., CPA, CA, ICD||Chief Financial Officer||N/A||N/A||1965|
|Ms. Joanne Schindler||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Marc Jasmin CPA, CMA||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Ms. Annie Tanguay B.Sc.||Sr. VP of Quality & Compliance||N/A||N/A||N/A|
|Delphine Davan||Director of Communications||N/A||N/A||N/A|
|Dr. Marianne Stanford||VP of R&D||N/A||N/A||N/A|
IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
IMV Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.